Recent

% | $
Quotes you view appear here for quick access.

VMware, Inc. Message Board

stocker4949 670 posts  |  Last Activity: 5 hours ago Member since: Aug 31, 2006
  • re test $37 to $38.

  • Reply to

    Letter From Taiwan - Standard Life Investments

    by sbacchus2003 Jan 26, 2016 1:21 AM
    stocker4949 stocker4949 Jan 26, 2016 4:02 PM Flag

    sbac, thanks for sharing it.

    Sentiment: Strong Buy

  • I am tired of holding and losing.

  • stocker4949 stocker4949 Jan 26, 2016 3:43 PM Flag

    Got in HIMX since late 2013 until now. Did not sell when it was over $17. This stock has been beaten really badly.

  • Reply to

    time to buy

    by bigmaida Jan 26, 2016 10:02 AM
    stocker4949 stocker4949 Jan 26, 2016 3:23 PM Flag

    HIMX was over $8.80 from their last earning beat. Someone has been stealing our money. HIMX shall have been $9 after the last positive earning beat and ov$10 if they beat earning again onFeb. 4.

    Sentiment: Strong Buy

  • Their earning is coming up on Feb. 4th and the stock now is only $7.30. I feel greatly cheated because if they beat earning again and stock jumps, we are lucky to get up to $9 again. I just feel someone has been stealing my money from this investment.

    Sentiment: Strong Buy

  • He told me patience will pay off. He is an analyst in the firm.

  • stocker4949 by stocker4949 Jan 26, 2016 1:53 PM Flag

    Cheers.

    Sentiment: Strong Buy

  • Reply to

    Lawsuit after lawsuit

    by harrisonlee2002 Jan 25, 2016 7:43 AM
    stocker4949 stocker4949 Jan 26, 2016 1:53 PM Flag

    I know your frustration, Harrison. I have held GWPH for a long time and I did not sell even when stock hit $133 for over $20 dollars a share of profit based on my strong belief that their drugs are going to bring so much blessings who those suffer long time epilispy.

    Sentiment: Strong Buy

  • Go private!

    Sentiment: Strong Buy

  • Array BioPharma

    Another biopharmaceutical player that insiders are loading up on here is Array BioPharma (ARRY - Get Report) , which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Insiders are buying this stock into large weakness, since shares have dropped sharply by 27.3% over the last three months.

    Array BioPharma has a market cap of $510 million and an enterprise value of $447 million. This stock trades at a premium valuation, with a trailing price-to-earnings of 31.6. Its estimated growth rate for this year is -785.7%, and for next year it's pegged at -10.4%. This is a cash-rich company, since the total cash position on its balance sheet is $159.30 million and its total debt is $108.81 million.

    STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks with serious upside potential in the next 12-months. Learn more.

    A beneficial owner just bought 925,000 shares, or about $3.39 million worth of stock, at $3.54 per share.

    Must Read: 5 Big Stocks to Save You in This Market

    From a technical perspective, Array BioPharma is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending over the last month and change, with shares moving lower from its high of $5.20 to its recent low of $3.40 a share. During that downtrend, shares of Array BioPharma have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has started to bounce modestly off its new 52-week low of $3.40 a share, and it's beginning to trend within range of triggering a near-term breakout trade.

    If you're in the bull camp on Array BioPharma, then I would look for long-biased trades as long as this stock is trending above its new 52-week low of $3.40 a share and then once it breaks out above some near-term overhead resistance at $3.75 a share and

    Sentiment: Strong Buy

  • Why You Shouldn't Bet Against GW Pharmaceuticals (GWPH) Stock
    Zacks
    By Zacks Equity Research
    January 12, 2016 9:43 AM
    56.77
    +2.42%
    GW Pharmaceuticals plc Watchlist
    56.77+1.34(2.42%)

    One stock that might be an intriguing choice for investors right now is GW Pharmaceuticals plc GWPH.This is because this security in the Medical Products space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

    This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical Products space as it currently has a Zacks Industry Rank of 52 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

    Meanwhile, GW Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

    In fact, over the past month, current quarter estimates have narrowed from a loss of $1.83 per share to a loss of $1.80 per share, while current year estimates have narrowed from a loss of $7.21 per share to a loss of $7.12 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal.

    So, if you are looking for a decent pick in a strong industry, consider GW Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

    Sentiment: Strong Buy

  • P/E (ttm):
    5.18

    EPS (ttm):
    2.28

    Sentiment: Strong Buy

  • 80% more upside from here.

    Sentiment: Strong Buy

  • HIMX is sitting on good cash for its R&D advancement and it carries no debt. Plus it gives shareholders good dividend while they invest in the company. This is really a very good investment to be in and I am surprised the stock is not over $10 by now. HIMX has signed contract with Microsoft, Sony, Samsung and Google. The Ex Microsoft CEO invested in his money and own 4% of HIMX last October. HIMX is aoing to be a huge shining star this year for solid growth.

    Sentiment: Strong Buy

  • Himax Is Poised For Growth

    Jan. 18, 2016 4:30 PM ET
    |
    About: Himax Technologies, Inc. (HIMX), Includes: FB, GOOG, GOOGL, MSFT

    Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)

    Summary

    •Himax Technologies has a number of contracts with big-name companies to create and implement its own displays into their devices.

    •2015 failed to be the year of AR/VR as a lot of developers didn’t meet their deadlines and most of the devices were rescheduled for 2016.

    •This year would finally be a year when AR and VR will take off. And Himax, in its current position, is a solid 'buy'.

    If by any chance you attended this year's Consumer Electronic Show, you would've seen a wide variety of virtual and augmented reality devices all around the exposition hall. And it's not a secret that in the next decade this technology will only increase its presence in our everyday life. So while a lot of companies are jumping into this field and creating their own versions of headsets, there would be a great demand for working components for these devices in the next few years.

    Himax Technologies (NASDAQ:HIMX) will play a big role in supplementing these components to major hardware developers. It already has a number of contracts with big-name companies to create and implement its own displays into their devices. And while AR and VR industries are gaining traction, more orders will come in the next few months, as more developers are releasing their consumer versions of the headsets. And when those new orders come, Himax's success will only be a matter of time.

    Catalysts for growth

    Let's look at the current developments in VR and AR field. Since 2012, when Oculus VR launched its first version of Oculus Rift a lot of changes occurred inside those both industries. The current picture looks like this:

    Sentiment: Strong Buy

  • Pozen: Unjustified Discount On Stock Offers A Great Investment Opportunity

    Nov. 28, 2015 9:49 AM ET
    |
    About: Pozen, Inc. (POZN)

    Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)

    Summary

    •Market overreaction to negative macroeconomic news and insider sales leave Pozen's stock currently undervalued.

    •The acquisition of Tribute Pharmaceuticals will diversify the company's product portfolio and provide growth for the merged firm, Aralez Pharmaceuticals.

    •Pozen's current financial performance proves the company's ability to create value even without FDA approval of its new product YOSPRALA, which is pending.

    Pozen, Inc. (NASDAQ:POZN) is a North Carolina based pharmaceutical firm in the business of developing and licensing specialty drugs for the treatment of acute and chronic pain, as well as novel therapies for other pain related conditions. The company sells its products primarily in the U.S. but also internationally. Pozen has a diverse product portfolio, offering multiple products for the treatment of migraine attacks. In addition, the company is awaiting FDA approval for YOSPRALA, an innovative drug providing the cardiovascular benefit of aspirin while causing less severe gastrointestinal side effects.

    Negative Macroeconomic News

    The Clinton effect led to a sector wide stock price decrease in the specialty drug industry, affecting biotechnology and pharmaceutical firms like Pozen. Presidential candidate Hillary Clinton posted on Twitter a statement criticizing the high prices of specialty drugs throughout the industry. She announced a plan to fight the rising prices. Her reaction was caused by a $736.50 price increase on one of Turing Pharmaceuticals' drugs in August. However, this price increase is only a special case and currently cannot be related to the whole industry.

    Sentiment: Buy

  • stocker4949 stocker4949 Jan 19, 2016 9:15 PM Flag

    WESTON GRAHAM M
    Director

  • 25-Aug-15 85,500 RAX Automatic Purchase at $29.24 per share.
    (Cost of $2,500,020)
    20-May-15 5,568 RAX Acquisition (Non Open Market) at $0 per share.
    18-Nov-14 58,480 RAX Purchase at $42.75 per share.
    (Cost of $2,500,020)

  • EOM. Stock is really cheap right now.

    Sentiment: Strong Buy

VMW
44.48+0.64(+1.46%)Feb 10 4:02 PMEST